Abstract Tumour necrosis factor alpha inhibitors, both inXiximab and adalimumab, have been approved for the treatment of both rheumatoid arthritis and Crohn's disease. A slight increase in the risk of infections in patients receiving immunosuppressants and/or biological agents has been reported. Here, we present the case of a 68-year-old woman aVected by Crohn's disease, myasthenia gravis, recurrent uveitis and rheumatoid arthritis who developed pneumonia during concomitant treatment with biological agents and conventional immunosuppressive drugs.
A 68-year-old woman aVected by myasthenia gravis, recurrent uveitis, rheumatoid arthritis (RA) and gallstones developed in the Wrst months of 2003 diarrhoea (about 5-6 intestinal movements for day, without blood) and abdominal pain. At that time the patient was treated with systemic corticosteroids (prednisone 10 mg/day) and non-steroidal antinXammatory drugs (NSAIDs) for rheumatoid arthritis, topical corticosteroids for recurrent uveitis, ursodeoxycholic acid for gallstones and cholinesterase inhibitors (pyridostigmine) for myasthenia gravis.
An ileocolonoscopy was performed showing ulcers in the terminal ileum. Histological examination of the ileal specimen showed the presence of histopathological Wndings suggesting the diagnosis of Crohn's disease (CD). A small intestine contrast ultrasonography (SICUS) was also performed showing thickening of bowel wall (3.8-6 mm) for the last 7 cm of the terminal ileum, supporting the hypothesis of CD. The patient was referred to our GI Unit, daily dose of prednisone was increased to 50 mg/day and maintenance treatment with mesalazine 2.4 g/day was started. NSAIDs were stopped. The patient failed to taper prednisone at a dose less than 10 mg/day, for the reappearance of abdominal pain in low right quadrant of the abdomen and articular pain. In November 2003, for the appearance of steroid-dependency and osteoporosis, treatment with inXiximab at a dose of 5 mg/kg at weeks 0, 2, and 6, and azathioprine (2 mg/kg per day) was started. Steroids were withdrawn and for 1 year the patient was in well-being, without abdominal and articular pain. Furthermore, there was complete remission of myasthenia gravis and neurologists stopped pyridostigmine treatment. In October 2004, the patient was referred to Emergency Unit due to abdominal pain in the upper and right quadrants of the abdomen and vomiting. Diagnosis of acute pancreatitis was made, azathioprine treatment was stopped, due to a Wrst hypothesis of drug-induced pancreatitis, and an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterectomy and stones extraction was performed. A cholecystectomy was not preformed due to opposing opinion of anaesthesists. Six months later, during April 2004, for the reappearance of articular pain Wrst and then abdominal pain prednisone 10 mg was started again. In 2006 due to the further need of NSAIDs and recurrence of uveitis due to the recurrence of uveitis treated by topical steroids, azathioprine was started again at a dose of 2 mg/kg per day. The E. Angelucci (&) · M. Cesarini · P. Vernia Gastroenterology Unit, University of Rome "Sapienza", Viale del Policlinico 155, 00161 Rome, Italy e-mail: erika.angelucci@yahoo.it drug was well tolerated without increase in pancreatic enzymes, but the patient failed to stop steroids over a 2-year period, because of reappearance of articular and abdominal symptoms within 1 month of steroids withdrawal. Another SICUS was performed showing an increased length of the involved terminal ileum (23 compared to 7 cm in 2003). Venous blood assessment revealed rise in the erythrocyte sedimentation rate (ESR) (60 mm/h), C-reactive protein (CRP) (18.4 g/dl) and Wbrinogen (604 U/ml). In June 2008, after a negative chest X-ray and PPD screening, induction treatment with adalimumab was started (160 mg at week 0 and 80 mg at week 2) followed by maintenance treatment (40 mg eow). At the beginning of September 2008 the patient stopped steroids. Two months after steroids withdrawal, the patient was well and venous blood assessment revealed normal value of ESR (9 mm/h), CRP (0.9 mg/dL) and white blood count (5,100/mmc). The patient continued maintenance treatment with adalimumab 40 mg eow and azathioprine (2 mg/kg per day). Few days before the eleventh injection of adalimumab 40 mg the patient developed fever, chest pain, severe fatigue, dyspnea and non-productive cough. Patient was referred to Emergency Unit. Laboratory Wndings showed increase in white blood count (15,290/mm 3 ) with prevalence of neutrophils (86%), normal number of lymphocytes (8%, 1,200/mm 3 ) and increase in ESR and CRP (45 mm/h and 4.5 mg/dL, respectively). Chest X-ray showed a consolidation in the lower left lobe (Fig. 1) . Pathogenic agent was not identiWed, but empirical antibiotic therapy with amoxicillin-clavulanic acid was started with success. Adalimumab and azathioprine were immediately stopped. Patient recovered in 1 week and chest X-ray performed 15 days later showed resolution of lobar consolidation. However, without immunosuppressive therapy, a relapse of myasthenia with prevalence of ocular symptoms (dyplopia, decrease of eyesight) appeared, requiring restart of therapy with steroids (prednisone 10 mg/day) and azathioprine (2 mg/kg per day). At the present time, patient is in well-being under these maintenance therapy.
Discussion
Tumour necrosis factor alpha (TNF-) inhibitors, both the humanized one (inXiximab) and the fully human (adalimumab) have been approved for the treatment of both rheumatoid arthritis and CD [1, 2] . A slight increase in the risk of infections due to prolonged immunosuppression was reported in rheumatological and IBD patients, especially in severe cases requiring concomitant and prolonged steroid use [3, 4] . In particular, several cases of pneumonia, including severe cases by Nocardia cyriacigeorgica [5] , Legionella pneumophila and Pneumocystis carinii, were reported in the recent years.
The safety of these agents on patients with myasthenia gravis has not been assessed. Only one case report showed the potential beneWt from therapy with inXiximab in one patient with myasthenia gravis, but the appearance of infectious side eVects, as in our patient, lead to withdrawal of this biological agent [6] . To our knowledge, this should be the Wrst report of use of adalimumab in a patient with myasthenia gravis.
